Inositol triphosphate pharmaceutical compositions
OwnerMatti Sireninventor
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition containing as a pharmaceutically active ingredient at least one isomer of inositol triphosphate (IP.sub.3) in an amount sufficient to reduce the negative effect of cadmium or aluminium in the body or inhibit or reduce the formation of free radicals in the body.
Claims21
A pharmaceutical composition comprising as a pharmaceutically active ingredient an isomer of inositol triphosphate, a salt thereof or an acid thereof and a pharmaceutically acceptable carrier, excipient or additive thereof, said isomer having the structural formula ##STR16## where (a) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydrogen;
- (b) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydrogen;
- (c) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.11 are hydrogen;
- (d) three of R.sub.1, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (e) three of R.sub.1, R.sub.3, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (f) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.11 are hydrogen;
- (g) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydrogen;
- (h) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.9 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.10 and R.sub.12 are hydrogen.
A pharmaceutical composition comprising, as a pharmaceutically active ingredient, an isomer of inositol triphosphate, a salt thereof or an acid thereof and a pharmaceutically acceptable carrier, excipient or additive thereof, said isomer having the structural formula ##STR17## where (a) R.sub.1, R.sub.3 and R.sub.12 are phosphate;
- R.sub.5, R.sub.8 and R.sub.9 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (b) R.sub.1, R.sub.3 and R.sub.8 are phosphate;
- R.sub.5, R.sub.9 and R.sub.12 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7 and R.sub.10 and R.sub.11 are hydrogen;
- (c) R.sub.3, R.sub.5 and R.sub.12 are phosphate;
- R.sub.1, R.sub.8, and R.sub.9 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (d) R.sub.1, R.sub.5 and R.sub.9 are phosphate;
- R.sub.3, R.sub.8 and R.sub.12 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (e) R.sub.1, R.sub.3 and R.sub.9 are phosphate;
- R.sub.5, R.sub.8 and R.sub.12 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (f) R.sub.1, R.sub.8 and R.sub.9 are phosphate;
- R.sub.3, R.sub.5, and R.sub.12 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (g) R.sub.1, R.sub.8 and R.sub.12 are phosphate;
- R.sub.3, R.sub.5 and R.sub.9 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (h) R.sub.5, R.sub.8 and R.sub.12 are phosphate;
- R.sub.1, R.sub.3 and R.sub.9 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (i) R.sub.1, R.sub.9 and R.sub.12 are phosphate;
- R.sub.3, R.sub.5 and R.sub.8 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (j) R.sub.5, R.sub.8 and R.sub.9 are phosphate;
- R.sub.1, R.sub.3 and R.sub.12 are hydroxyl;
- R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (k) R.sub.3, R.sub.8 and R.sub.9 are phosphate;
- R.sub.1, R.sub.5 and R.sub.12 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- (l) R.sub.3, R.sub.8 and R.sub.12 are phosphate;
- R.sub.1, R.sub.5 and R.sub.9 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10, and R.sub.11 are hydrogen;
- (m) R.sub.8, R.sub.9 and R.sub.12 are phosphate;
- R.sub.1, R.sub.3 and R.sub.5 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen
- (n) R.sub.1, R.sub.5 and R.sub.12 are phosphate;
- R.sub.3, R.sub.8 and R.sub.9 are hydroxyl;
- and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;
- or
- (o) R.sub.3, R.sub.9 and R.sub.12 are phosphate;
- R.sub.1 and R.sub.5 and R.sub.8 are hydroxyl;
- and R.sub.2, R.sub.4, and R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen.
Dependencies are inferred from the claim text.